All News

Acepodia and JW Therapeutics Enter into Option and License Agreement for Off-the-shelf NK Cell Therapies
Ref: GlobeNewswire
Tags: Press ReleaseJW Therapeutics AcepodiaLeukaemias Corporate Affairs LicensingACE1702 ACE1655
Cytokinetics Announces Licensing Collaboration and Royalty Monetization Deals with RTW Investments Focused to CK-3773274, Next-Generation Cardiac Myosin Inhibitor
Ref: GlobeNewswire
Tags: Press ReleaseCytokineticsCardiomyopathies Corporate Affairs LicensingCK-3773274
Fosun Pharma Announces its Licensed COVID-19 Vaccine Product Receives Acceptance Notice of Clinical Trial Application by NMPA
Ref: PR Newswire
Tags: Press ReleaseBioNTech Fosun PharmaceuticalCOVID-19 Immunisation NMPARegulatory AffairsBNT162b1
IMV Updates Rapid Progress on COVID-19 Vaccine Program
Ref: Business Wire
Tags: Press ReleaseIMVCOVID-19 Immunisation Health CanadaRegulatory AffairsDPX-COVID-19
Recce Pharmaceuticals Adds Biotech Veteran Alan W. Dunton M.D. to its Board of Directors
Ref: GlobeNewswire
Tags: People NewsCorMedix Emisphere J&J Oragenics Palatin Panacos Roche Recce Pharmaceuticals Corporate Affairs
Deciphera Announces Australian Therapeutic Goods Administration’s Approval of QINLOCK (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Ref: Business Wire
Tags: Press ReleaseDecipheraGIST TGAMarketing & Sales Regulatory AffairsQinlock
Landos Biopharma Announces First Human Dosing in a Phase 1 Study of NX-13, its Novel Candidate for Inflammatory Bowel Disease
Ref: GlobeNewswire
Tags: Press ReleaseLandos BiopharmaIBD Clinical Research (R&D)NX-13
Albireo Enrolls First Patient in Phase 3 Clinical Trial of Odevixibat in Biliary Atresia
Ref: GlobeNewswire
Tags: Press ReleaseAlbireo Clinical Research (R&D)odevixibat
AlloVir Appoints Two New Members to the Board of Directors
Ref: Business Wire
Tags: People NewsAlloVir Gilead Merck & Co. Corporate Affairs
Calithera Biosciences Appoints Scott Garland to Board of Directors
Ref: GlobeNewswire
Tags: People NewsAlexion Calithera Biosciences Exelixis Karyopharm Portola Relypsa Roche Corporate Affairs